CRNA raises NOK 620 million for growth through 2030
CRNA said circVec technology advances showed up to 60x–200x improved gene expression in vivo and it has 23 collaborations underway. The company raised NOK 620 million to fund expanded gene and cell therapy programs through 2030.
CRNA said major advances in circVec technology supported strong R&D and business development efforts, with up to 60x-200x improved gene expression demonstrated in vivo and 23 collaborations underway. The company said NOK 620 million raised secures funding through 2030 and will support expanded programs in gene therapy and cell therapy.